NCT06291324Active, not recruiting
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 46 (estimated)
- First submitted
- 26 Feb 2024
- Start date
- 4 Oct 2024
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Pancreatic cancer
- NCT number
- NCT06291324
What you commit to
- Study type: Observational
- Planned participants: 46
- From 4 Oct 2024 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any documented, clinically significant cardiac-related abnormality per enrolling investigator that could compromise the outcome of the study. NOTE: The heart rate data collected using the WATD will not be used for patient care.
- Other factors or conditions, per investigator discretion, for which participation in the study would not be in the patient's best interest or could interfere with study assessment results or preclude study completion
Other
- No internet, Wi-Fi access or email account
- No access to a smartphone or mobile device
Who the study is looking for
- Written informed consent and HIPAA authorization for release of personal health information
- Patients pancreatic or invasive breast cancer per enrolling investigator who is planning on or has started anti-cancer treatment. Note: Patients with cancer who are not planning to receive anti-cancer treatment are not eligible for study participation
- Patients with any severity of self-reported fatigue per enrolling investigator
- Age ≥ 18 years at the time of consent
- Ability to read and understand the English language
- As determined by the enrolling investigator, the ability of the participant to understand and comply with study procedures (i.e., completing questionnaires and device return) for the entire length of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.